According to a press release, a first-in-man feasibility study focusing on a novel use of the RenalGuard system to manage fluids during diuretic therapy in congestive heart failure patients suffering from fluid overload has shown positive results for the system. A previous meta-analysis found that the system reduces all-cause mortality in patients undergoing cardiac interventions.
The Science Museum (London, UK) has unveiled a special exhibit to commemorate the 50th anniversary of the world’s first heart transplant, which took place in South Africa in December 1967.
Janssen has submitted a supplemental new drug application to the US FDA for two new indications for rivaroxaban (Xarelto, which is marketed by Bayer in Europe): reducing the risk of major cardiovascular events such as cardiac death, myocardial infarction or stroke in patients with coronary artery disease and/or peripheral arterial disease; and for reducing the risk of acute limb ischaemia in patients with peripheral arterial disease.
Apple has launched the Apple Heart Study app, a first-of-its-kind research study using Apple Watch’s heart rate sensor to collect data on irregular heart rhythms and notify users who may be experiencing atrial fibrillation (AF).
Philips has acquired VitalHealth, a provider of cloud-based population health management solutions for the delivery of personalised care outside of the hospital. Headquartered in the Netherlands, a press release reports, VitalHealth’s products and services are being used by more than 100 healthcare networks in various countries including the USA, India, China, and the Netherlands.
4C Medical Technologies has won the Best Technology Parade Presentation award—at the 2017 Innovations in Cardiovascular Interventions (ICI) meeting (3–5 December, Tel Aviv, Israel)—for its transcatheter device for treating mitral regurgitation.
Fan Chung (National Heart & Lung Institute, Imperial College London, UK) and colleagues report in The Lancet that even short-term (two-hour) exposure to tiny particles of soot or dust found in traffic fumes on busy roads appears to thwart the benefits of walking on the heart and lungs among older adults (aged 60 or over). They report that short-term exposure to pollution is associated with stiffening of the arteries and impaired lung function, and strengthens the case to reduce vehicle emissions so that everyone can enjoy the health benefits of physical activity.
According to the interim results of the first-ever multi-country online survey on cardiovascular disease risk awareness and knowledge among people living with type 2 diabetes, one in three respondents (943 overall) living with the condition consider their risk of cardiovascular disease to be low. Furthermore, the results indicate that one in six respondents had never discussed type 2 diabetes and cardiovascular risk with a healthcare professional.
Data from the regional emergency cardiovascular (RESCUe) network indicate that patients who have had a ST-segment elevation myocardial infarction (STEMI) and who are increased risk of future events are more likely to be under-treated with preventive pharmacological therapy than STEMI patients with fewer risk factors. They also show that, unsurprisingly, optimal medical therapy is associated with increased one-year survival.
CorInnova has been awarded second prize in the “2017 InnoSTARS” life science competition for its EpicHeart soft-robotic heart assist device. The on-blood-contacting device is designed to be delivered minimally invasively to support heart function.
Following ORBITA, which indicated percutaneous coronary intervention (PCI) did not provide benefit over a sham procedure in patients with stable coronary artery disease, the three-year results of the FAME-2 trial indicate that fractional flow reserve (FFR)-guided PCI improves clinical outcomes compared with medical management alone.
Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott) is substantially reduced when the device is not implanted into very small vessels. However, the study also showed greater ischaemia-driven target lesion failure with the scaffold than with a permanent metallic everolimus-eluting stent (Xience, Abbott)—indicating that device as well as technique improvements is necessary
A report—modified from US global health recommendations from the National Academies of Sciences, Engineering and Medicine (previously the Institute of Medicine) and published in Journal of the American College of Cardiology—states that the USA must prioritise its health resources toward detecting and treating non-communicable diseases such as cardiovascular disease.
Cordis and Medinol have announced that the US FDA has approval the Elunir drug-eluting stent for the treatment of patients with coronary artery disease. The stent, a press release reports, is designed with a novel metallic spring tip; it has the narrowest strut width of any stent on the US market.
The first human implantation of the VenusA Plus retrievable valve system was completed successfully at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU) on 23 November. Wang Jian’an (president of SAHZU) announced that China has completed its first successful human implantation of a retrievable transcatheter aortic valve implantation (TAVI) device.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos